Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Sarcoma 1Gynecologic 1

Conditions

Lymphoma 900Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 617Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Lymphoma, Follicular 516Hodgkin Disease 442Lymphoma, Mantle-Cell 421Leukemia 410Lymphoma, B-Cell, Marginal Zone 289Burkitt Lymphoma 285Recurrence 277Leukemia, Myeloid, Acute 276Multiple Myeloma 250Myelodysplastic Syndromes 237Waldenstrom Macroglobulinemia 187Lymphoma, B-Cell 179Lymphoma, Large-Cell, Immunoblastic 153Lymphoma, T-Cell, Cutaneous 143Leukemia, Myelogenous, Chronic, BCR-ABL Positive 127Lymphoma, T-Cell, Peripheral 123Mycosis Fungoides 118Myeloproliferative Disorders 112Lymphoma, Large-Cell, Anaplastic 107Dendritic Cell Sarcoma, Interdigitating 103Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 102Neoplasms 98Lymphoma, Extranodal NK-T-Cell 96Hematologic Neoplasms 96Sezary Syndrome 94

Interventions

Vincristine 1Rituximab 1Prednisone 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × HIV Seropositivity × Lymphoid × Clear all
NCT06919679 2025-04-09

BASTION

University of Cologne

Phase 2 Not yet recruiting
35 enrolled
Lymphoid

HIV Seropositivity, Hodgkin Disease

NCT01092182 2023-04-27

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
194 enrolled 19 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, HIV Seropositivity, HIV Infections, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡